Overview

A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets

Status:
Completed

Trial end date:
2018-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the bioequivalence of Xisimin (loratadine) compared with Clarityne in healthy participants receiving a single dose of 10 milligram (mg) under fasting condition as part of Cohort 1 and under fed condition as part of Cohort 2.

Phase:

Phase 1

Details

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Loratadine